Coulter Partners secures Chief Commercial Officer for Albumedix

Written by: Pharmiweb editor
Published On: 8 Jun 2020

Coulter Partners was delighted to partner once again with Albumedix, the world leader in recombinant human albumin (rAlb), to secure the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.  
Gregor brings more than 25 years’ experience within the life science sector and extensive operational experience from previous commercial roles at Catalent Pharma Solutions and Next Pharma, and most recently as Chief Commercial Officer at IDT-Biologika GmbH. His clear focus on commercial execution and building strong client relationships has driven consistent growth across several segments in the advanced therapy space throughout his career.  
Speaking on the new appointment to the Executive team, Jonas Skjødt Møller, Chief Executive Officer, Albumedix, commented, “We are thrilled to welcome Gregor to Albumedix. He is an extremely accomplished executive, displaying the right balance between being an effective negotiator and a people-focused leader, with an impressive commercial track record. We see a sustainable growth opportunity for the business, driven by our strong market momentum enabling stable and scalable therapeutics to reach patients globally. With Gregor joining our team, we are well-placed to drive further growth together with our customers and take Albumedix to the next level, both in terms of market reach, patient impact and value creation. I thank the team at Coulter Partners for their outstanding professional support in achieving this high calibre appointment.”  
At Albumedix, Gregor’s focus will be on strengthening the company´s position as partner of choice within advanced therapies, and on driving revenue growth and business acceleration across key market segments. He will be responsible for establishing strategic partnerships in new markets, expanding and progressing Albumedix’ customer portfolio, and extending the global footprint of the company. Albumedix are actively working on expanding capacity of their manufacturing site to accommodate this growing demand in advanced therapies and biopharmaceuticals. Together with Jonas and the rest of the Executive Leadership at Albumedix, Gregor will support the next wave of expansion and commercial reach.  
Commenting on his new appointment, Gregor said, “I am delighted to join the Albumedix ‘family’; a passionate and like-minded group of talented individuals all striving toward a common goal to address critical challenges with biologics and vaccines through strategic partnering and pioneering solutions. Albumedix offers a unique, and highly sought-after product range that has the potential to dramatically transform the development of complex drugs, such as cellular therapies, next-generation viral vaccines and gene therapies. We have a lot to be proud of, and with the market growing rapidly, Albumedix has so much to offer. There really is so much to explore and I am in the right place at the right time to maximize this exciting opportunity.”  
For more information please visit https://albumedix.com/ 
About Albumedix – Dedicated to Better Health  
Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our recombinant human albumin products. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albuminenabled therapies today as we were when we started 30 years ago.